Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Joel Sandler, associate partner, healthcare (North America) Drug: Ivonescimab Company: Summit/Akeso Indication: EGFR-mutant non-small cell lung cancer (NSCLC) Stage: Phase III Background: Ivonescimab is a first-in-class PD-1/VEGF bispecific that unifies checkpoint blockade and anti-angiogenesis initially being explored in the EGFR-mutated NSCLC population who already received AstraZenecas osimertinib
Individuals with mood disorders, autoimmune conditions, seizure disorders, or those taking certain medications should consult a healthcare provider before adding melatonin
Teva announces FDA approval and launch of generic Saxenda (liraglutide injection) first generic GLP-1 indicated for weight loss
Competitive analysis profiles Hims & Hers and Ro alongside LifeMD and Noom
How to use Facebook Ad Library like a pro with Foreplay Using the Facebook Ad Library with Foreplay is an effective strategy for researching and organizing ad inspirations
US$ 29.12
US$ 24.48
US$ 28.16
US$ 21.09
US$ 21.08
US$ 26.84
US$ 22.03
US$ 24.54
US$ 27.21
US$ 29.80
